These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

460 related items for PubMed ID: 25797236

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study.
    Gallos ID, Krishan P, Shehmar M, Ganesan R, Gupta JK.
    Hum Reprod; 2013 Nov; 28(11):2966-71. PubMed ID: 23975691
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up.
    Gallos ID, Krishan P, Shehmar M, Ganesan R, Gupta JK.
    Hum Reprod; 2013 May; 28(5):1231-6. PubMed ID: 23466671
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Dominick S, Hickey M, Chin J, Su HI.
    Cochrane Database Syst Rev; 2015 Dec 09; 2015(12):CD007245. PubMed ID: 26649916
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Chin J, Konje JC, Hickey M.
    Cochrane Database Syst Rev; 2009 Oct 07; (4):CD007245. PubMed ID: 19821400
    [Abstract] [Full Text] [Related]

  • 10. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Romero SA, Young K, Hickey M, Su HI.
    Cochrane Database Syst Rev; 2020 Dec 21; 12(12):CD007245. PubMed ID: 33348436
    [Abstract] [Full Text] [Related]

  • 11. The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia: an Australian study and systematic review.
    Buttini MJ, Jordan SJ, Webb PM.
    Aust N Z J Obstet Gynaecol; 2009 Jun 21; 49(3):316-22. PubMed ID: 19566568
    [Abstract] [Full Text] [Related]

  • 12. Comparative effects of different treatments based on the levonorgestrel intrauterine system in endometrial carcinoma and endometrial hyperplasia patients: a network meta-analysis.
    Tao M, Wu T, Zhou X, Du X, Ling K, Liang Z.
    Arch Gynecol Obstet; 2024 Sep 21; 310(3):1315-1329. PubMed ID: 38980346
    [Abstract] [Full Text] [Related]

  • 13. Levonorgestrel-releasing intrauterine system versus systemic progestins in management of endometrial hyperplasia: A systemic review and meta-analysis.
    Elassall GM, Sayed EG, Abdallah NA, El-Zohiry MM, Radwan AA, AlMahdy AM, Sedik AS, Elazeem HASA, Shazly SA.
    J Gynecol Obstet Hum Reprod; 2022 Oct 21; 51(8):102432. PubMed ID: 35760334
    [Abstract] [Full Text] [Related]

  • 14. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis.
    Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK.
    Am J Obstet Gynecol; 2010 Dec 21; 203(6):547.e1-10. PubMed ID: 20934679
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of levonorgestrel-releasing intrauterine system versus oral progestins in treatment of simple endometrial hyperplasia without atypia.
    Ismail MT, Fahmy DM, Elshmaa NS.
    Reprod Sci; 2013 Jan 21; 20(1):45-50. PubMed ID: 23203322
    [Abstract] [Full Text] [Related]

  • 16. Management of Endometrial Hyperplasia With a Levonorgestrel-Releasing Intrauterine System: A Korean Gynecologic-Oncology Group Study.
    Kim MK, Seong SJ, Kim JW, Jeon S, Choi HS, Lee IH, Lee JH, Ju W, Song ES, Park H, Ryu HS, Lee C, Kang SB.
    Int J Gynecol Cancer; 2016 May 21; 26(4):711-5. PubMed ID: 26905333
    [Abstract] [Full Text] [Related]

  • 17. The efficacy of levonorgestrel intrauterine systems for endometrial protection: a systematic review.
    Wan YL, Holland C.
    Climacteric; 2011 Dec 21; 14(6):622-32. PubMed ID: 22017273
    [Abstract] [Full Text] [Related]

  • 18. Levonorgestrel-Releasing Intrauterine Systems Versus Oral Cyclic Medroxyprogesterone Acetate in Endometrial Hyperplasia Therapy: A Meta-Analysis.
    Yuk JS, Song JY, Lee JH, Park WI, Ahn HS, Kim HJ.
    Ann Surg Oncol; 2017 May 21; 24(5):1322-1329. PubMed ID: 27896507
    [Abstract] [Full Text] [Related]

  • 19. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia.
    El Behery MM, Saleh HS, Ibrahiem MA, Kamal EM, Kassem GA, Mohamed Mel S.
    Reprod Sci; 2015 Mar 21; 22(3):329-34. PubMed ID: 25001020
    [Abstract] [Full Text] [Related]

  • 20. Progestogens or progestogen-releasing intrauterine systems for uterine fibroids (other than preoperative medical therapy).
    Sangkomkamhang US, Lumbiganon P, Pattanittum P.
    Cochrane Database Syst Rev; 2020 Nov 23; 11(11):CD008994. PubMed ID: 33226133
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.